Economic evaluation of tandem mass spectrometry screening in California.
OBJECTIVE
On the basis of California's experience implementing a pilot tandem mass spectrometry (MS/MS) screening program, an economic evaluation was conducted to determine the economic benefits and costs of a statewide MS/MS screening program.


METHODS
Cost-effectiveness, benefit/cost, and cost-utility analyses were conducted with a base-case set of assumptions. The base-case assumptions were varied by using a set of more-favorable and less-favorable assumptions to test the robustness of the analysis findings.


RESULTS
The total estimated, annualized, incremental costs of MS/MS screening of 540,000 births in California were nearly $5.7 million; 83 affected newborns would be identified. Screening would reduce the expected lifetime costs of medical care for affected newborns by $7.2 million ($9.0 million in the best-case scenario and $1.8 million in the worst-case scenario). When all program costs and savings were considered, screening saved $1.5 million ($3.4 million saved in the best-case scenario and $3.8 million additional costs in the worst-case scenario). With only incremental program costs, the cost per life saved was $708,000 and the cost per case detected was $68,000. With consideration of the projected lifetime medical care costs, the total cost per case detected was $132,000. MS/MS screening produced a benefit/cost ratio of $9.32 ($11.67 with the best-case set of assumptions and $4.34 with the worst-case set of assumptions). In this analysis, the benefits of screening exceeded total program costs by $47.1 million (the net incremental benefit). In the worst-case scenario, the net incremental benefit of screening was $18.9 million. Screening saved 949 quality-adjusted life-years (QALYs) and saved $1628 per QALY in the base case analysis. Under the worst-case scenario, the cost per QALY was $14,922.


CONCLUSIONS
We found that the benefits of MS/MS screening outweighed the costs and that the net benefits were significant and robust in various scenarios with various conservative underlying assumptions.
Feuchtbaum
Lisa
L
Genetic Disease Branch, California Department of Health Services, Richmond, CA 94804, USA. lfeuchtb@dhs.ca.gov
Cunningham
George
G
D002140:California; D003362:Cost-Benefit Analysis; D006801:Humans; D007231:Infant, Newborn; D013058:Mass Spectrometry / Q000191:economics*; D015997:Neonatal Screening / Q000191:economics*; D010865:Pilot Projects; D015397:Program Evaluation